NC(=O)c1ccc[n+]([C@H]2O[C@@H](COP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@H](O)[C@@H]2O)c1
The rule of three is typically followed by orally active drugs, which have a molecular weight of <300, a c LogP of ≤3, a hydrogen bond donor count of ≤3 and a hydrogen bond acceptor count of ≤3. Does the molecule comply with the rule of three?